At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 130 enrolled
Drug / intervention
Baricitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease
In Brief
A Phase 2 clinical trial evaluating Baricitinib and Placebo for Diabetic Kidney Disease. Completed, enrolled 130 participants across 45 sites in 4 countries.
Detailed Summary
This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Kidney Disease
CountriesJapan, Mexico, Puerto Rico, United States
CollaboratorsIncyte Corporation
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedSep 2012
Primary CompletionSep 2014
Study CompletionNov 2014
TodayJul 2026
First PostedSep 11, 2012
Enrollment StartAug 1, 2012
Primary CompletionSep 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 13.8 years ago
Interventions
Baricitinibdrug
Administered orally
Placebodrug
Administered orally